Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abeona Therapeutics (NQ: ABEO )

7.570 +0.040 (+0.53%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 386,264
Open 7.500
Bid (Size) 7.000 (2)
Ask (Size) 7.560 (1)
Prev. Close 7.530
Today's Range 7.200 - 7.690
52wk Range 2.830 - 9.010
Shares Outstanding 27,355,037
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga

Performance

YTD
+36.89%
+36.89%
1 Month
+0.53%
+0.53%
3 Month
+51.40%
+51.40%
6 Month
+82.85%
+82.85%
1 Year
+144.98%
+144.98%

More News

Read More
ABEO Stock Earnings: Abeona Therapeutics Misses EPS for Q4 2023
Via InvestorPlace
Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
From Abeona Therapeutics Inc.
Via GlobeNewswire
Recap: Abeona Therapeutics Q3 Earnings
Via Benzinga
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Processa Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces $50 Million Credit Facility
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
The 7 Most Undervalued Penny Stocks to Buy in October 2023
Via InvestorPlace
Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa
From Abeona Therapeutics Inc.
Via GlobeNewswire
3 Biotech Blockbusters to Turn $5,000 Into $50,000
Via InvestorPlace
Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces Participation in Upcoming Investor Conferences
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Reports Second Quarter 2023 Financial Results
From Abeona Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023
From Abeona Therapeutics Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.